Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. operates within China, focusing on the entire lifecycle of heparin-based pharmaceuticals – from their initial research and development to manufacturing and sales. Their products are primarily utilized for the treatment of cardiovascular and cerebrovascular diseases. The company offers a broad range of heparin compounds, including crude heparin sodium and refined heparin sodium raw materials. Their portfolio also features a variety of injectable heparin preparations, such as standard heparin sodium injections. Furthermore, they produce both the raw materials and finished injectable forms for several low molecular weight heparins, specifically low molecular weight heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium. Established in the year 2000, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is headquartered in Shijiazhuang, China.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E.